Mer­ck touts new da­ta for break­through pneu­mo­coc­cal vac­cine as it heads to PhI­II tri­als

Two months af­ter Mer­ck’s pneu­mo­coc­cal vac­cine can­di­date V116 won break­through ther­a­py des­ig­na­tion based on Phase I/II tri­al da­ta, Mer­ck is now start­ing to share da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER